Marisa Tungsiripat
Overview
Explore the profile of Marisa Tungsiripat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
264
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Procop G, Taege A, Starkey C, Tungsiripat M, Warner D, Schold J, et al.
Diagn Microbiol Infect Dis
. 2017 Jun;
89(1):44-46.
PMID: 28647065
The processing of specimens often occurs in a central processing area within laboratories. We demonstrated that plasma centrifuged in the central laboratory but allowed to remain within the primary tube...
3.
Wangsiricharoen S, Ligon C, Gedmintas L, Dehrab A, Tungsiripat M, Bingham 3rd C, et al.
Arthritis Care Res (Hoboken)
. 2016 Jun;
69(3):449-452.
PMID: 27332039
Objective: To estimate the incidence of serious infections in patients with HIV infection and autoimmune disease who were treated with tumor necrosis factor (TNF) inhibitors, and to compare these rates...
4.
Ali M, Magee M, Dave J, Ofotokun I, Tungsiripat M, Jones T, et al.
J Acquir Immune Defic Syndr
. 2014 Aug;
67 Suppl 1:S27-39.
PMID: 25117959
Globally, the HIV epidemic is evolving. Life expectancy for HIV-infected individuals has been extended because of more effective and more widely available antiretroviral therapy. As a result, chronic noncommunicable diseases...
5.
Tungsiripat M, El-Bejjani D, Rizk N, Hu B, Ross A, Walker U, et al.
J AIDS Clin Res
. 2012 Dec;
3(8):174.
PMID: 23227444
OBJECTIVE: We aim to evaluate the mechanisms of rosiglitazone-induced fat recovery in HIV+ patients with lipoatrophy on thymidine Nucleoside Reverse Transcriptase Inhibitors (NRTI) sparing regimens. METHOD: Measures of limb fat...
6.
Tungsiripat M, El-Bejjani D, Rizk N, Dogra V, ORiordan M, Ross A, et al.
AIDS Res Hum Retroviruses
. 2010 Oct;
27(3):295-302.
PMID: 20969457
Rosiglitazone may be useful for the treatment of antiretroviral therapy-associated lipoatrophy, but an association with cardiovascular disease (CVD) has been questioned in diabetics. We evaluated rosiglitazone's effect on surrogate markers...
7.
Tungsiripat M, Kitch D, Glesby M, Gupta S, Mellors J, Moran L, et al.
AIDS
. 2010 May;
24(11):1781-4.
PMID: 20495438
Several studies have reported improvement in lipids after antiretroviral therapy switches to tenofovir disoproxil fumarate (TDF)-containing regimens. We assessed lipid-lowering effects of TDF by adding it to a stable antiretroviral...
8.
Tungsiripat M, El Bejjani D, Rizk N, ORiordan M, Ross A, Hileman C, et al.
AIDS
. 2010 May;
24(9):1291-8.
PMID: 20453626
Objective: Thymidine reverse transcriptase inhibitors (tNRTI) are strong inhibitors of PPAR-gamma and clearly implicated as a cause of lipoatrophy. Thiazolidenediaones (TZD), potent PPAR-gamma agonists, would be expected to be beneficial...
9.
Tungsiripat M, ORiordan M, Storer N, Harrill D, Ganz J, Libutti D, et al.
HIV Clin Trials
. 2009 Nov;
10(5):314-9.
PMID: 19906628
Objectives: Although physician- and patient-rated diagnoses of lipoatrophy are currently used as a basis for inclusion into clinical trials, few studies have compared physician- or patient-rated lipoatrophy severity with objective...
10.
Ross A, Rizk N, ORiordan M, Dogra V, El-Bejjani D, Storer N, et al.
Clin Infect Dis
. 2009 Aug;
49(7):1119-27.
PMID: 19712036
Background: Human immunodeficiency virus (HIV)-infected patients are at increased risk of cardiovascular disease, which may be related to chronic inflammation and endothelial dysfunction despite virological control with antiretroviral therapy. The...